Catalyst Pharmaceutical (CPRX) closed the last trading session at $19.24, gaining 13.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $30.14 indicates a 56.7% upside potential. The average comprises seven short-term price targets ranging from a low of $26 to a high of $38, with a standard deviation of $3.89. While the lowest estimate indicates an increase of 35.1% from the curren ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. - ...

Financial Data and Key Metrics Changes - In Q2 2024, Catalyst Pharmaceuticals reported total revenues of $122.7 million, a 23.2% increase compared to Q2 2023, driven by strong organic growth from FIRDAPSEE and AGAMREE [4][12][19] - Net income before income taxes was $55.8 million, a 15% increase from $48.5 million in Q2 2023, with GAAP net income of $40.8 million or $0.33 per diluted share, an 8% year-over-year increase [19][20] - Non-GAAP net income for Q2 2024 was $69.6 million or $0.56 per diluted share, compared to $60.4 million or $0.53 per diluted share in Q2 2023 [20] Business Line Data and Key Metrics Changes - FIRDAPSEE achieved Q2 net sales of $77.4 million, a 19.2% increase year-over-year, attributed to steady new patient enrollments and a low discontinuation rate [13][14] - FYCOMPA generated Q2 net revenues of $36.5 million, with expectations for stable revenues in the second half of 2024 [15] - AGAMREE reported Q2 product net revenues of $8.7 million, exceeding initial launch expectations, with 46% of new enrollments transitioning from EMFLAZA [16][17] Market Data and Key Metrics Changes - The company received US approval for FIRDAPSEE's expanded maximum daily dose of 100 milligrams, enhancing treatment flexibility for healthcare professionals [6] - The ongoing collaboration with DyDo Pharma in Japan is expected to yield a NDA decision for FIRDAPSEE by the end of Q3 or early Q4 2024 [7] Company Strategy and Development Direction - The company is focused on a threefold growth strategy: outstanding execution, portfolio diversification, and targeted ex-US partnerships [10][11] - Catalyst aims to continue its buy and build plan, enhancing its capabilities in identifying and launching products that deliver value [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving total revenue at the upper end of the previously guided range of $455 million to $475 million for 2024, driven by strong performance across its product portfolio [5][19] - The company remains committed to advancing patient care and unlocking growth potential while maintaining a strong balance sheet [24] Other Important Information - The company ended Q2 2024 with cash and cash equivalents of $375.7 million, significantly up from $137.6 million at the end of 2023, driven by a capital raise and operational cash generation [22][23] - Research and development expenses decreased to $3 million in Q2 2024 from $4 million in Q2 2023, while SG&A expenses increased due to the launch of AGAMREE [22] Q&A Session Summary Question: Was there a bolus in AGAMREE sales due to pent-up demand? - Management confirmed significant pent-up demand leading to strong sales in Q2, with expectations for continued interest moving forward [25][26] Question: How will the new higher dose of FIRDAPSEE impact patient discontinuation rates? - Management does not expect an increase in discontinuation rates due to the new dosing flexibility, as the majority of discontinuations occur within the first six months of therapy [30][31] Question: What is the company's strategy for business development? - The company is focused on orphan and differentiated orphan products, with a broad approach to potential opportunities in the neuro space and beyond [31] Question: How is the patient mix for AGAMREE expected to evolve? - Management anticipates the patient mix will remain stable, with no significant impact from the generic entrance of EMFLAZA observed so far [34][36] Question: What is the status of ongoing litigation related to FIRDAPSEE? - Management is working diligently to resolve ongoing litigation favorably but refrained from commenting in detail [37] Question: What is the company's approach to future business development deals? - The company is inclined to pursue deals that enhance income diversity, with a preference for cash-funded deals initially, followed by potential leverage for larger transformational opportunities [39][40]

Catalyst Pharmaceuticals, Inc. (CPRX) reported adjusted earnings of 56 cents per share for the second quarter of 2024, beating the Zacks Consensus Estimate of 42 cents. The company reported adjusted earnings of 53 cents in the year-ago quarter. Total revenues, the majority of which comprised product revenues, amounted to $122.7 million in the reported quarter, representing growth of 23% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $111.6 million. Catalyst's top line pri ...

Catalyst Pharmaceutical (CPRX) reported $122.71 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 23.2%. EPS of $0.56 for the same period compares to $0.33 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $111.76 million, representing a surprise of +9.80%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being $0.42. While investors closely watch year-over-year changes in headline numbers -- revenue and ...

Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of $122.7 Million, Representing a 23.2% YoY Increase FIRDAPSE® Q2 2024 Net Product Revenues of $77.4 Million, Reflecting Strong Organic 19.2% YoY Growth AGAMREE® Q2 2024 Net Product Revenues of $8.7 Million Demonstrates a Strong Start to U.S. Commercialization FYCOMPA® Q2 2024 Net Product Revenues of $36.5 Million, Representing a 5.7% Y ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 | --- | --- | |--------------------------------------------------------------------------------------------|---------------------------------------- ...

"Our expanded partnership with Catalyst highlights the intrinsic value of our collaboration in developing innovative treatments for rare diseases, including DMD, and exemplifies our shared dedication to improving health outcomes across the U.S. and Canada. Together, we are committed to delivering novel therapies and bridging clinically significant treatment gaps," stated John McKendry, CEO and President of Kye Pharmaceuticals. About AGAMREE® (vamorolone) "We are pleased to enter into this agreement with Kye ...

CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2024 financial results after the market close on Wednesday, August 7, 2024. Conference Call & Webcast Details The webcast will be accessible under t ...

Catalyst's management team will host a conference call and webcast on Thursday, August 8, 2024, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Date: Time: US/Canada Dial-in Number: International Dial-in Number: August 8, 2024 8:30 AM ET (877) 407-8912 (201) 689-8059 About Catalyst Pharmaceuticals, Inc. For more information about Catalyst Pharmaceuticals, Inc., please visit the Company's website atwww.catalystpharma.com. For Full Prescribing and Safety Information for ...